Investing.com - Financial Markets Worldwide

FTSE 100 tracks Asia gains on COVID-19 treatment hopes

Published 24/08/2020, 08:12
© Reuters.
UK100
-
US500
-
AZN
-
FTMC
-

(For a live blog on European stocks, type LIVE/ in an Eikon
news window)
* FTSE 100 up 1.2%, FTSE 250 adds 0.5%

Aug 24 (Reuters) - The FTSE 100 jumped on Monday, tracking
Asian markets as U.S. regulators authorised a COVID-19 treatment
over the weekend, while AstraZeneca rose on a report the U.S.
government was considering fast-tracking its experimental
vaccine.
The drugmaker AZN.L gained 1.5% and was the top boost to
the FTSE 100 as the report said one option being explored would
involve the U.S. health regulator awarding "emergency use
authorisation" in October to the potential vaccine. The export-laden FTSE 100 .FTSE was up 1.2% after ending
Friday with its first weekly loss in three as fresh Brexit
concerns compounded fears over the UK's post-pandemic economic
recovery.
The blue-chip index has gained about 23% from its March
lows, but lagged the U.S. benchmark S&P 500 .SPX , which is
scaling record highs on historic fiscal and monetary stimulus
and hopes that the worst of the pandemic's economic damage was
over.
On Sunday, the U.S. Food & Drug Administration said it
authorised the use of blood plasma from patients who had
recovered from COVID-19 as a treatment for the disease.
The UK's mid-cap FTSE 250 .FTMC rose 0.5%, led by
financial, industrial and consumer discretionary stocks.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.